Catabasis Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Published: Jun, 2015 | Pages: 36 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Catabasis Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Catabasis Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Catabasis Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Catabasis Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Catabasis Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Catabasis Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Catabasis Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

- Evaluate Catabasis Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Catabasis Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Catabasis Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Catabasis Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Catabasis Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Catabasis Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Catabasis Pharmaceuticals, Inc. Snapshot 5
Catabasis Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Catabasis Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Catabasis Pharmaceuticals, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Catabasis Pharmaceuticals, Inc. - Pipeline Products Glance 11
Catabasis Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Catabasis Pharmaceuticals, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Catabasis Pharmaceuticals, Inc. - Drug Profiles 14
CAT-2003 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
CAT-1004 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
CAT-1000 Series 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
CAT-2054 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CAT-1040 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CAT-1041 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CAT-1920 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CAT-2000 Series 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CAT-4000 Series 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
CAT-4001 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Catabasis Pharmaceuticals, Inc. - Pipeline Analysis 25
Catabasis Pharmaceuticals, Inc. - Pipeline Products by Target 25
Catabasis Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 26
Catabasis Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 27
Catabasis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 28
Catabasis Pharmaceuticals, Inc. - Recent Pipeline Updates 29
Catabasis Pharmaceuticals, Inc. - Dormant Projects 33
Catabasis Pharmaceuticals, Inc. - Locations And Subsidiaries 34
Head Office 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 35
Disclaimer 36

List of Tables

Catabasis Pharmaceuticals, Inc., Key Information 5
Catabasis Pharmaceuticals, Inc., Key Facts 5
Catabasis Pharmaceuticals, Inc. - Pipeline by Indication, 2015 8
Catabasis Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 9
Catabasis Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 10
Catabasis Pharmaceuticals, Inc. - Phase II, 2015 11
Catabasis Pharmaceuticals, Inc. - Phase I, 2015 12
Catabasis Pharmaceuticals, Inc. - Preclinical, 2015 13
Catabasis Pharmaceuticals, Inc. - Pipeline by Target, 2015 25
Catabasis Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 26
Catabasis Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 27
Catabasis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 28
Catabasis Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 29
Catabasis Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 33